Akèy › Kansè Ezofajyen › Distrik Columbia › Washington
Etid klinik pou Kansè Ezofajyen nan Washington, DC
9 etid pou Kansè Ezofajyen ap chèche patisipan nan sit nan ak bò kote Washington (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
The Vanguard Study: Testing a New Way to Screen for Cancer
Ap rekriteVolontè an sante akeyi
- Walter Reed National Military Medical Center, Bethesda · 7 mi lwen
Evaluation of Cell Changes in Blood and Tissue in Cancers of the Lung, Esophagus and Lung Lining
Ap rekriteEtid obsèvasyon
- National Institutes of Health Clinical Center, Bethesda · 7 mi lwen
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
- MedStar Georgetown University Hospital, Washington D.C.
- MedStar Washington Hospital Center, Washington D.C.
- Walter Reed National Military Medical Center, Bethesda · 7 mi lwen
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
Ap rekriteFaz 1
- Georgetown University Medical Center, Washington D.C.
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
Ap rekriteFaz 3
- Research Site, Silver Spring · 7 mi lwen
A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer
Ap rekriteFaz 1
- Georgetown University Medical Center, Washington D.C.
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
Ap rekriteFaz 1/2
- National Institutes of Health, Bethesda · 7 mi lwen
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
Ap rekriteFaz 1/2
- The George Washington University Cancer Center (site 212), Washington D.C.
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Ap rekriteEtid obsèvasyon
- Massive Bio SYNERGY-AI site, Silver Spring · 7 mi lwen
- Massive Bio SYNERGY-AI site, Bethesda · 7 mi lwen
Etid Kansè Ezofajyen nan lòt vil
- Houston, TX36 etid
- Boston, MA23 etid
- New York City, NY22 etid
- Nashville, TN19 etid
- St. Louis, MO17 etid
- Pittsburgh, PA15 etid
- Los Angeles, CA15 etid
- Baldwin Park, CA14 etid
- Grand Rapids, MI14 etid
- Philadelphia, PA13 etid
- San Antonio, TX12 etid
- Dallas, TX11 etid
Lòt etid nan Washington
- Kansè (tout kalite)58 etid
- Kansè Poumon ki pa ti selil55 etid
- Kansè nan tete46 etid
- Kansè Metastatik43 etid
- Kansè poumon41 etid
- Kansè pwostat38 etid
- Obèsite33 etid
- Kansè kolorektal29 etid
- Maladi kadyovaskilè28 etid
- Kansè vejik26 etid
- Leksemi mieloïd egi24 etid
- Kansè ovè23 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.